{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:46:04Z","timestamp":1793400364359,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA228019"],"award-info":[{"award-number":["CA228019"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI130471"],"award-info":[{"award-number":["AI130471"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005188","name":"Tobacco-Related Disease Research Program","doi-asserted-by":"publisher","award":["T33IR6609"],"award-info":[{"award-number":["T33IR6609"]}],"id":[{"id":"10.13039\/100005188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>T cell scarcity in tumor tissues poses a critical challenge to cancer immunotherapy. Here we manipulate the tumor vasculature, an essential regulator of immune cell trafficking, to reinvigorate anti-tumor T cell responses in \u201ccold\u201d tumors. We show that ectopic pan-endothelial expression of COUP-TFII, a master transcription factor for venous development, induces molecular programs of post-capillary venules in tumor endothelium. Venular reprogramming selectively promotes T cell recruitment into tumors, inhibits tumor growth in mouse models of breast and pancreatic cancers, and sensitizes tumors to immune checkpoint blockade and adoptive T cell transfer therapies. Mechanistic studies show that enhanced recruitment of anti-tumor T cells and tumor inhibition are mediated by COUP-TFII-induced vascular adhesion receptors. Our study supports a pivotal role of vascular endothelial cells in governing tumor immune evasion, and proposes venular reprogramming as a therapeutic strategy to bolster anti-tumor immunity and immunotherapy.<\/jats:p>","DOI":"10.1038\/s41467-025-62399-1","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T13:54:48Z","timestamp":1755006888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["COUP-TFII-mediated reprogramming of the vascular endothelium counteracts tumor immune evasion"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3250-6546","authenticated-orcid":false,"given":"Yu","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin F.","family":"Brulois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh T.","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2373-0917","authenticated-orcid":false,"given":"Junliang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8786-7907","authenticated-orcid":false,"given":"Eugene C.","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"62399_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"62399_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"62399_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.trecan.2018.04.001","volume":"4","author":"AH Morrison","year":"2018","unstructured":"Morrison, A. H., Byrne, K. T. & Vonderheide, R. H. Immunotherapy and prevention of pancreatic cancer. Trends Cancer 4, 418\u2013428 (2018).","journal-title":"Trends Cancer"},{"key":"62399_CR4","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1016\/S1470-2045(20)30234-5","volume":"21","author":"M Ochoa de Olza","year":"2020","unstructured":"Ochoa de Olza, M., Navarro Rodrigo, B., Zimmermann, S. & Coukos, G. Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. Lancet Oncol. 21, e419\u2013e430 (2020).","journal-title":"Lancet Oncol."},{"key":"62399_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74\u201380 (2015).","journal-title":"Science"},{"key":"62399_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen, D. S. & Schumacher, T. N. T Cell Dysfunction in Cancer. Cancer Cell 33, 547\u2013562 (2018).","journal-title":"Cancer Cell"},{"key":"62399_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang, Y. et al. Improving immune-vascular crosstalk for cancer immunotherapy. Nat. Rev. Immunol. 18, 195\u2013203 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"62399_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1126\/science.272.5258.60","volume":"272","author":"EC Butcher","year":"1996","unstructured":"Butcher, E. C. & Picker, L. J. Lymphocyte homing and homeostasis. Science 272, 60\u201366 (1996).","journal-title":"Science"},{"key":"62399_CR9","first-page":"4265","volume":"52","author":"NZ Wu","year":"1992","unstructured":"Wu, N. Z., Klitzman, B., Dodge, R. & Dewhirst, M. W. Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res. 52, 4265\u20134268 (1992).","journal-title":"Cancer Res"},{"key":"62399_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/sj.bjc.6604929","volume":"100","author":"JA Nagy","year":"2009","unstructured":"Nagy, J. A., Chang, S. H., Dvorak, A. M. & Dvorak, H. F. Why are tumour blood vessels abnormal and why is it important to know?. Br. J. Cancer 100, 865\u2013869 (2009).","journal-title":"Br. J. Cancer"},{"key":"62399_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.gde.2004.12.005","volume":"15","author":"P Baluk","year":"2005","unstructured":"Baluk, P., Hashizume, H. & McDonald, D. M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15, 102\u2013111 (2005).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"62399_CR12","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm.2537","volume":"17","author":"SM Weis","year":"2011","unstructured":"Weis, S. M. & Cheresh, D. A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 17, 1359\u20131370 (2011).","journal-title":"Nat. Med."},{"key":"62399_CR13","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMra0706596","volume":"358","author":"RS Kerbel","year":"2008","unstructured":"Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 358, 2039\u20132049 (2008).","journal-title":"N. Engl. J. Med."},{"key":"62399_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain, R. K. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26, 605\u2013622 (2014).","journal-title":"Cancer Cell"},{"key":"62399_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298\u2013307 (2011).","journal-title":"Nature"},{"key":"62399_CR16","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","volume":"28","author":"HL Kindler","year":"2010","unstructured":"Kindler, H. L. et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28, 3617\u20133622 (2010).","journal-title":"J. Clin. Oncol."},{"key":"62399_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378\u2013390 (2008).","journal-title":"N. Engl. J. Med."},{"key":"62399_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nature03511","volume":"435","author":"LR You","year":"2005","unstructured":"You, L. R. et al. Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. Nature 435, 98\u2013104 (2005).","journal-title":"Nature"},{"key":"62399_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17291-5","volume":"11","author":"K Brulois","year":"2020","unstructured":"Brulois, K. et al. A molecular map of murine lymph node blood vascular endothelium at single cell resolution. Nat. Commun. 11, 3798 (2020).","journal-title":"Nat. Commun."},{"key":"62399_CR20","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1210\/me.2011-1305","volume":"26","author":"X Chen","year":"2012","unstructured":"Chen, X., Qin, J., Cheng, C. M., Tsai, M. J. & Tsai, S. Y. COUP-TFII is a major regulator of cell cycle and Notch signaling pathways. Mol. Endocrinol. 26, 1268\u20131277 (2012).","journal-title":"Mol. Endocrinol."},{"key":"62399_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1055\/s-0029-1241862","volume":"42","author":"C Brunssen","year":"2010","unstructured":"Brunssen, C. et al. COUP-TFII is regulated by high glucose in endothelial cells. Horm. Metab. Res. 42, 81\u201387 (2010).","journal-title":"Horm. Metab. Res."},{"key":"62399_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34991-2","volume":"13","author":"TT Dinh","year":"2022","unstructured":"Dinh, T. T. et al. An NKX-COUP-TFII morphogenetic code directs mucosal endothelial addressin expression. Nat. Commun. 13, 7448 (2022).","journal-title":"Nat. Commun."},{"key":"62399_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11248-006-9056-9","volume":"16","author":"SA Davie","year":"2007","unstructured":"Davie, S. A. et al. Effects of FVB\/NJ and C57Bl\/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Res. 16, 193\u2013201 (2007).","journal-title":"Transgenic Res."},{"key":"62399_CR24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1084\/jem.181.2.669","volume":"181","author":"K Ley","year":"1995","unstructured":"Ley, K. et al. Sequential contribution of L- and P-selectin to leukocyte rolling in vivo. J. Exp. Med. 181, 669\u2013675 (1995).","journal-title":"J. Exp. Med."},{"key":"62399_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/cvr\/cvv154","volume":"107","author":"RP McEver","year":"2015","unstructured":"McEver, R. P. Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovasc. Res. 107, 331\u2013339 (2015).","journal-title":"Cardiovasc. Res."},{"key":"62399_CR26","doi-asserted-by":"publisher","first-page":"24838","DOI":"10.1074\/jbc.274.35.24838","volume":"274","author":"A Leppanen","year":"1999","unstructured":"Leppanen, A. et al. A novel glycosulfopeptide binds to P-selectin and inhibits leukocyte adhesion to P-selectin. J. Biol. Chem. 274, 24838\u201324848 (1999).","journal-title":"J. Biol. Chem."},{"key":"62399_CR27","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1182\/blood.V86.7.2760.2760","volume":"86","author":"S Kanwar","year":"1995","unstructured":"Kanwar, S. et al. Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules. Blood 86, 2760\u20132766 (1995).","journal-title":"Blood"},{"key":"62399_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4049\/jimmunol.137.1.245","volume":"137","author":"ML Dustin","year":"1986","unstructured":"Dustin, M. L., Rothlein, R., Bhan, A. K., Dinarello, C. A. & Springer, T. A. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J. Immunol. 137, 245\u2013254 (1986).","journal-title":"J. Immunol."},{"key":"62399_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/intimm\/12.3.241","volume":"12","author":"C Faveeuw","year":"2000","unstructured":"Faveeuw, C., Di Mauro, M. E., Price, A. A. & Ager, A. Roles of alpha(4) integrins\/VCAM-1 and LFA-1\/ICAM-1 in the binding and transendothelial migration of T lymphocytes and T lymphoblasts across high endothelial venules. Int. Immunol. 12, 241\u2013251 (2000).","journal-title":"Int. Immunol."},{"key":"62399_CR30","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/ni.2983","volume":"15","author":"M Lee","year":"2014","unstructured":"Lee, M. et al. Transcriptional programs of lymphoid tissue capillary and high endothelium reveal control mechanisms for lymphocyte homing. Nat. Immunol. 15, 982\u2013995 (2014).","journal-title":"Nat. Immunol."},{"key":"62399_CR31","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nm.4123","volume":"22","author":"H Jiang","year":"2016","unstructured":"Jiang, H. et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat. Med. 22, 851\u2013860 (2016).","journal-title":"Nat. Med."},{"key":"62399_CR32","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nature09002","volume":"465","author":"Y Wang","year":"2010","unstructured":"Wang, Y. et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 465, 483\u2013486 (2010).","journal-title":"Nature"},{"key":"62399_CR33","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1242\/dev.01808","volume":"132","author":"N Takamoto","year":"2005","unstructured":"Takamoto, N. et al. COUP-TFII is essential for radial and anteroposterior patterning of the stomach. Development 132, 2179\u20132189 (2005).","journal-title":"Development"},{"key":"62399_CR34","doi-asserted-by":"publisher","first-page":"15313","DOI":"10.1074\/jbc.M115.650051","volume":"290","author":"R Matsumura","year":"2015","unstructured":"Matsumura, R. et al. Novel antibodies reactive with sialyl Lewis X in both humans and mice define its critical role in leukocyte trafficking and contact hypersensitivity responses. J. Biol. Chem. 290, 15313\u201315326 (2015).","journal-title":"J. Biol. Chem."},{"key":"62399_CR35","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","volume":"317","author":"JR Groom","year":"2011","unstructured":"Groom, J. R. & Luster, A. D. CXCR3 in T cell function. Exp. Cell Res. 317, 620\u2013631 (2011).","journal-title":"Exp. Cell Res."},{"key":"62399_CR36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/icb.2010.158","volume":"89","author":"JR Groom","year":"2011","unstructured":"Groom, J. R. & Luster, A. D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89, 207\u2013215 (2011).","journal-title":"Immunol. Cell Biol."},{"key":"62399_CR37","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1172\/JCI6993","volume":"104","author":"F Mach","year":"1999","unstructured":"Mach, F. et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J. Clin. Invest. 104, 1041\u20131050 (1999).","journal-title":"J. Clin. Invest."},{"key":"62399_CR38","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1158\/1078-0432.CCR-13-0525","volume":"19","author":"DE Sanford","year":"2013","unstructured":"Sanford, D. E. et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2\/CCR2 axis. Clin. Cancer Res. 19, 3404\u20133415 (2013).","journal-title":"Clin. Cancer Res."},{"key":"62399_CR39","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","volume":"73","author":"JB Mitchem","year":"2013","unstructured":"Mitchem, J. B. et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 73, 1128\u20131141 (2013).","journal-title":"Cancer Res."},{"key":"62399_CR40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","volume":"17","author":"TM Nywening","year":"2016","unstructured":"Nywening, T. M. et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 17, 651\u2013662 (2016).","journal-title":"Lancet Oncol."},{"key":"62399_CR41","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00262-017-1988-9","volume":"66","author":"V Umansky","year":"2017","unstructured":"Umansky, V., Blattner, C., Gebhardt, C. & Utikal, J. CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma. Cancer Immunol. Immunother. 66, 1015\u20131023 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"62399_CR42","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang, Y. et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl Acad. Sci. USA 109, 17561\u201317566 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"62399_CR43","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/0092-8674(90)90009-4","volume":"62","author":"R Montesano","year":"1990","unstructured":"Montesano, R. et al. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 62, 435\u2013445 (1990).","journal-title":"Cell"},{"key":"62399_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03600-6","volume":"9","author":"MA Meyer","year":"2018","unstructured":"Meyer, M. A. et al. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nat. Commun. 9, 1250 (2018).","journal-title":"Nat. Commun."},{"key":"62399_CR45","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.ccell.2022.11.002","volume":"40","author":"Y Hua","year":"2022","unstructured":"Hua, Y. et al. Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1(+) T lymphocyte niches through a feed-forward loop. Cancer Cell 40, 1600\u20131618 e1610 (2022).","journal-title":"Cancer Cell"},{"key":"62399_CR46","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ccell.2023.02.002","volume":"41","author":"G Vella","year":"2023","unstructured":"Vella, G., Hua, Y. & Bergers, G. High endothelial venules in cancer: regulation, function, and therapeutic implication. Cancer Cell 41, 527\u2013545 (2023).","journal-title":"Cancer Cell"},{"key":"62399_CR47","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ccell.2022.01.002","volume":"40","author":"A Asrir","year":"2022","unstructured":"Asrir, A. et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell 40, 318\u2013334.e319 (2022).","journal-title":"Cancer Cell"},{"key":"62399_CR48","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cmet.2023.01.010","volume":"35","author":"D Zhang","year":"2023","unstructured":"Zhang, D. et al. PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy. Cell Metab. 35, 517\u2013534.e518 (2023).","journal-title":"Cell Metab."},{"key":"62399_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37807-z","volume":"14","author":"DJ Kim","year":"2023","unstructured":"Kim, D. J. et al. Priming a vascular-selective cytokine response permits CD8(+) T-cell entry into tumors. Nat. Commun. 14, 2122 (2023).","journal-title":"Nat. Commun."},{"key":"62399_CR50","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nnano.2014.84","volume":"9","author":"JE Dahlman","year":"2014","unstructured":"Dahlman, J. E. et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat. Nanotechnol. 9, 648\u2013655 (2014).","journal-title":"Nat. Nanotechnol."},{"key":"62399_CR51","doi-asserted-by":"publisher","first-page":"609","DOI":"10.15252\/emmm.201506078","volume":"8","author":"J Korbelin","year":"2016","unstructured":"Korbelin, J. et al. A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases. EMBO Mol. Med. 8, 609\u2013625 (2016).","journal-title":"EMBO Mol. Med."},{"key":"62399_CR52","doi-asserted-by":"publisher","first-page":"110196","DOI":"10.1016\/j.celrep.2021.110196","volume":"38","author":"X Zhang","year":"2022","unstructured":"Zhang, X. et al. Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA. Cell Rep. 38, 110196 (2022).","journal-title":"Cell Rep."},{"key":"62399_CR53","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41586-018-0288-7","volume":"559","author":"T Su","year":"2018","unstructured":"Su, T. et al. Single-cell analysis of early progenitor cells that build coronary arteries. Nature 559, 356\u2013362 (2018).","journal-title":"Nature"},{"key":"62399_CR54","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fcvm.2020.00052","volume":"7","author":"M Xiang","year":"2020","unstructured":"Xiang, M. et al. A single-cell transcriptional roadmap of the mouse and human lymph node lymphatic vasculature. Front. Cardiovasc. Med. 7, 52 (2020).","journal-title":"Front. Cardiovasc. Med."},{"key":"62399_CR55","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.cell.2020.01.015","volume":"180","author":"J Kalucka","year":"2020","unstructured":"Kalucka, J. et al. Single-cell transcriptome atlas of murine endothelial cells. Cell 180, 764\u2013779.e720 (2020).","journal-title":"Cell"},{"key":"62399_CR56","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.cell.2018.05.061","volume":"174","author":"D van Dijk","year":"2018","unstructured":"van Dijk, D. et al. Recovering gene interactions from single-cell data using data diffusion. Cell 174, 716\u2013729.e727 (2018).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62399-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62399-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62399-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:57:11Z","timestamp":1757379431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62399-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62399"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62399-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"15 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7457"}}